Bharat Biotech’s COVID-19 Vaccine (COVAXIN) Phase 3 Trial Update
On 3rd July, 2021, Bharat Biotech concluded Phase 3 Trials of COVID-19 vaccine. The company claimed to have achieved the overall efficacy of 77.8 percent.
Whereas, for the Delta variant (BBV152) the company claimed the efficacy of 65.2 percent. The company updated on Twitter that “COVAXIN Proven SAFE in India’s Largest Efficacy Trial,”
The Director General of the Indian Council of Medical Research Dr Balram Bhargava said that “Covaxin will “immensely contribute to protect the global community against the deadly SARS-CoV-2 virus”
“I am delighted to note that Covaxin, developed by ICMR and Bharat Biotech under an effective public-private partnership, has demonstrated an overall efficacy of 77.8 per cent in India’s largest Covid Phase 3 clinical trial thus far. Our scientists at ICMR and BBIL have worked tirelessly to deliver a truly effective vaccine of the highest international standards. The successful development of Covaxin has consolidated the position of Indian academia and industry in the global arena,” Dr Bhargava said.